News Releases & Research Results Safe thrombolytic therapy with alteplase for cerebral infarction of unknown onset time without the FLAIR imaging findings of cerebral infarction

The results of a domestic research project multicenter conducted by its principal investigator, Vice Director Kazunori Toyoda of the National Cerebral and Cardiovascular Center.

• Thrombolytic therapy by intravenous alteplase infusion is effective for cerebral infarction within 4.5 hours after onset. However, it has been rarely indicated for cerebral infarction of unknown onset time.
• The present randomly assigned study (*) demonstrated that thrombolytic therapy by intravenous infusion could be safely performed if head MRI findings could be obtained within a short time after onset.
  * Treatment regimens are randomly assigned to examine their effects.
• In the future, a pooled analysis will be conducted with similar overseas studies to further examine the efficacy and safety of the treatment.

This research project was conducted with the support of the Practical Research Project for Life-Style related Diseases including Cardiovascular Diseases and Diabetes Mellitus by AMED.

The results of were published online in Stroke on April 6.